|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Henry Ford Health System |
|---|---|
| Information provided by: | Henry Ford Health System |
| ClinicalTrials.gov Identifier: | NCT00294502 |
Purpose
To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment (“antibiotic lock solution - ALS”) to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.
| Condition | Intervention | Phase |
|---|---|---|
|
ESRD |
Drug: Gentamycin/citrate, Minocycline/EDTA |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Estimated Enrollment: | 120 |
| Study Start Date: | September 2003 |
| Estimated Study Completion Date: | May 2004 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Michigan | |
| Henry Ford Hospital | |
| Detroit, Michigan, United States, 48202 | |
| Principal Investigator: | Antanole Bearabe, MD | Henry Ford Hospital |
More Information
| ClinicalTrials.gov Identifier: | NCT00294502 History of Changes |
| Other Study ID Numbers: | 3008 |
| Study First Received: | February 21, 2006 |
| Last Updated: | February 21, 2006 |
| Health Authority: | United States: Institutional Review Board |
|
Gentamicins Minocycline Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses |
Pharmacologic Actions Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |